AFIB · As filed with the SEC
Acutus Medical income statement, by fiscal year
The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations and Comprehensive Loss · USD thousands, except per-share amounts
| USD thousands, except per-share amounts | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|
| Revenue | 20,157 | 7,164 | 3,031 |
| Cost of products sold | 19,144 | 10,301 | 4,941 |
| Gross profit (loss) | 1,013 | (3,137) | (1,910) |
| Operating expenses (income): | |||
| Research and development | 0 | 3,482 | 3,118 |
| Selling, general and administrative | 10,436 | 14,066 | 20,315 |
| Goodwill impairment | — | 0 | 12,026 |
| Payments | 1,448 | — | — |
| Change in fair value of contingent consideration | 0 | 123 | 1,053 |
| Gain on sale of business | (10,814) | (9,080) | (79,465) |
| Total operating expenses | 1,070 | 8,591 | (42,953) |
| Loss from operations | (57) | (11,728) | 41,043 |
| Other income (expense): | |||
| Loss on debt extinguishment | — | 0 | (7,947) |
| Change in fair value of warrant liability | 215 | 2,937 | 33 |
| Interest income | — | 2,588 | 868 |
| Interest expense | — | (5,655) | (5,149) |
| Interest income | 763 | — | — |
| Interest expense | (5,758) | — | — |
| Other revenue | 301 | — | — |
| Total other expense, net | (4,479) | (130) | (12,195) |
| Loss from continuing operations before income taxes | (4,536) | (11,858) | 28,848 |
| Income tax expense | 0 | 63 | 15 |
| Net loss from continuing operations | (4,536) | (11,921) | 28,833 |
| Discontinued operations: | |||
| Loss from discontinued operations before income taxes | (4,999) | (69,530) | (68,382) |
| Income tax expense - discontinued operations | 12 | 212 | 67 |
| Loss from discontinued operations | (5,011) | (69,742) | (68,449) |
| Net loss | (9,547) | (81,663) | (39,616) |
| Other comprehensive income (loss): | |||
| Unrealized gain on marketable securities | 0 | 7 | 39 |
| Foreign currency translation adjustment | 98 | (4) | (691) |
| Comprehensive loss | (9,449) | (81,660) | (40,268) |
| Net loss per share, basic and diluted: | |||
| Loss from continuing operations, basic (in dollars per share) | (0.15) | (0.41) | 1.02 |
| Loss from discontinued operations, basic (in dollars per share) | (0.17) | (2.40) | (2.42) |
| Net loss per common share, basic (in dollars per share) | (0.32) | (2.81) | (1.40) |
| Net earnings (loss) per share, diluted: | |||
| Loss from continuing operations, (in dollars per share) | (0.15) | (0.41) | 0.78 |
| Loss from discontinued operations , diluted (in dollars per share) | (0.17) | (2.40) | (2.42) |
| Net loss per common share, diluted (in dollars per share) | (0.32) | (2.81) | (1.40) |
| Weighted average number of common shares outstanding, basic (in shares) | 29,768,208 | 29,095,294 | 28,471,389 |
| Weighted average number of common shares outstanding, diluted- continuing operations (in shares) | — | 29,095,294 | 37,152,367 |
| Weighted average number of common shares outstanding, diluted- discontinued operations and net loss per common share (in shares) | — | 29,095,294 | 28,471,389 |
| Weighted average number of common shares outstanding, diluted- continuing operations (in shares) | 29,768,208 | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.